Capricor Therapeutics CAPR Business Segments — Nonoperating Income Expense

Similar metrics at other companies

ALMSSingle Reportable — Nonoperating Income Expense

$5.36M+109%

POWISingle Reportable — Nonoperating Income Expense

$2.47M-22.1%

SRRKSingle Reportable — Other Nonoperating Income Expense

$3.49M+248%

ACLSSingle Reportable — Nonoperating Income Expense

$2.68M-31.8%

QURESingle Reportable — Other Nonoperating Income Expense

$199K-96.1%

MMSISingle Reportable — Nonoperating Income Expense

$9.39M+405%

Questions, answered.

What is Capricor Therapeutics's business segments — nonoperating income expense?

Capricor Therapeutics (CAPR) reported business segments — nonoperating income expense of $2.83M in Q1 2026.

How has Capricor Therapeutics's business segments — nonoperating income expense changed year-over-year?

Capricor Therapeutics's business segments — nonoperating income expense increased by 378.8% year-over-year, from $591.35K to $2.83M.

What does business segments — nonoperating income expense mean?

This represents the net total of all financial activities not directly related to the company's primary biotechnology research and commercial operations. It aggregates interest income, interest expenses, and other non-core financial items. This metric is essential for understanding the company's total financial health beyond its R&D performance.